Sirnaomics Ltd. and Bloomage Biotech Forge Strategic Partnership to Advance Next-Gen Life Science Pipelines

Reuters09-08

<a href="https://laohu8.com/S/SRNMF">Sirnaomics Ltd.</a> and Bloomage Biotech Forge Strategic Partnership to Advance Next-Gen Life Science Pipelines

Sirnaomics Ltd., a prominent biopharmaceutical company specializing in advanced RNAi therapeutics, has announced a strategic equity investment by Bloomage Biotech. Through this partnership, Bloomage Biotech has acquired a 9.44% stake in Sirnaomics for approximately HKD 138 million. The collaboration aims to accelerate the development and commercialization of Sirnaomics' aesthetics, longevity intervention, and regenerative medicine programs. Bloomage Biotech will leverage its expertise in hyaluronic acid biomanufacturing, glycobiology, and cell biology to enhance Sirnaomics' RNAi delivery platforms. This alliance will focus on the STP705 targeted fat reduction program and other siRNA-based aesthetic pipeline assets, while also exploring broader opportunities in precision-delivery products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: HK67536) on September 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2565257247?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 12:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565257247","market":"us","top_or_hot":-1,"title":"Sirnaomics Ltd. and Bloomage Biotech Forge Strategic Partnership to Advance Next-Gen Life Science Pipelines","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SRNMF\">Sirnaomics Ltd.</a> and Bloomage Biotech Forge Strategic Partnership to Advance Next-Gen Life Science Pipelines\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sirnaomics Ltd., a prominent biopharmaceutical company specializing in advanced RNAi therapeutics, has announced a strategic equity investment by Bloomage Biotech. Through this partnership, Bloomage Biotech has acquired a 9.44% stake in Sirnaomics for approximately HKD 138 million. The collaboration aims to accelerate the development and commercialization of Sirnaomics' aesthetics, longevity intervention, and regenerative medicine programs. Bloomage Biotech will leverage its expertise in hyaluronic acid biomanufacturing, glycobiology, and cell biology to enhance Sirnaomics' RNAi delivery platforms. This alliance will focus on the STP705 targeted fat reduction program and other siRNA-based aesthetic pipeline assets, while also exploring broader opportunities in precision-delivery products.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: HK67536) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sirnaomics Ltd. and Bloomage Biotech Forge Strategic Partnership to Advance Next-Gen Life Science Pipelines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSirnaomics Ltd. and Bloomage Biotech Forge Strategic Partnership to Advance Next-Gen Life Science Pipelines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-08 12:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SRNMF\">Sirnaomics Ltd.</a> and Bloomage Biotech Forge Strategic Partnership to Advance Next-Gen Life Science Pipelines\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sirnaomics Ltd., a prominent biopharmaceutical company specializing in advanced RNAi therapeutics, has announced a strategic equity investment by Bloomage Biotech. Through this partnership, Bloomage Biotech has acquired a 9.44% stake in Sirnaomics for approximately HKD 138 million. The collaboration aims to accelerate the development and commercialization of Sirnaomics' aesthetics, longevity intervention, and regenerative medicine programs. Bloomage Biotech will leverage its expertise in hyaluronic acid biomanufacturing, glycobiology, and cell biology to enhance Sirnaomics' RNAi delivery platforms. This alliance will focus on the STP705 targeted fat reduction program and other siRNA-based aesthetic pipeline assets, while also exploring broader opportunities in precision-delivery products.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: HK67536) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02257","symbol_name":"圣诺医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL5cD8V:1","article_id":"2565257247","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565257247","pubTimestamp":1757305006,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sirnaomics Ltd., a prominent biopharmaceutical company specializing in advanced RNAi therapeutics, has announced a strategic equity investment by Bloomage Biotech. Through this partnership, Bloomage Biotech has acquired a 9.44% stake in Sirnaomics for approximately HKD 138 million. The collaboration aims to accelerate the development and commercialization of Sirnaomics' aesthetics, longevity intervention, and regenerative medicine programs. Bloomage Biotech will leverage its expertise in hyaluronic acid biomanufacturing, glycobiology, and cell biology to enhance Sirnaomics' RNAi delivery platforms. This alliance will focus on the STP705 targeted fat reduction program and other siRNA-based aesthetic pipeline assets, while also exploring broader opportunities in precision-delivery products.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02257":"圣诺医药-B","BK1161":"生物科技"},"translate_title":"Sirnaomics Ltd.与华熙生物建立战略合作伙伴关系，推进下一代生命科学管线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02257":0.9},"content_text":"Sirnaomics Ltd. and Bloomage Biotech Forge Strategic Partnership to Advance Next-Gen Life Science Pipelines\n    \n\n        Sirnaomics Ltd., a prominent biopharmaceutical company specializing in advanced RNAi therapeutics, has announced a strategic equity investment by Bloomage Biotech. Through this partnership, Bloomage Biotech has acquired a 9.44% stake in Sirnaomics for approximately HKD 138 million. The collaboration aims to accelerate the development and commercialization of Sirnaomics' aesthetics, longevity intervention, and regenerative medicine programs. Bloomage Biotech will leverage its expertise in hyaluronic acid biomanufacturing, glycobiology, and cell biology to enhance Sirnaomics' RNAi delivery platforms. This alliance will focus on the STP705 targeted fat reduction program and other siRNA-based aesthetic pipeline assets, while also exploring broader opportunities in precision-delivery products.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: HK67536) on September 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2565257247","isCrawlerRequest":true}